SecBot SecBot
PRESS-RELEASE ·Filed Nov 3, 2026

PTCT

PTC Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed13d 19h ago WireGlobeNewswire
Press release · Buyback
Actionable Insight • Neutral

The buyback signals management's confidence in cash flow and valuation, but execution pace is at management's discretion. Monitor actual repurchase activity in future filings to gauge conviction; the authorization does not obligate PTC to buy shares.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$68.12
T+0 close · Nov 3, 2026 · via day close
Latest settled
−5.84%
T+5 · $64.14 · next T+20 in 15d
Vs SPY
−5.26%
α at T+5
Latest observation
−6.68%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $68.12entry
  2. T+1 · 13d ago +1.25%α −0.40% · $68.97
  3. T+5 · 7d ago −5.84%α −5.26% · $64.14
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PTC Therapeutics announced a $500 million share repurchase program, representing ~9.3% of its $5.4B market cap. The buyback follows strong Q3 2026 results reported 5 days ago, where total revenue of $357.6M beat consensus and full-year product revenue guidance was raised to $960M-$990M.

Key Financial Metrics

Deal Value
$500.0M

Key Facts

  • Board authorized up to $500 million in share repurchases
  • Repurchases may be made through open-market transactions, privately negotiated deals, or accelerated share repurchases
  • Authorization represents ~9.3% of current market cap ($5.4B)
  • Follows Q3 2026 earnings beat (revenue $357.6M vs $305.0M consensus) and raised product revenue guidance to $960M-$990M

Financial Impact

$500 million share repurchase authorization, ~9.3% of market cap

shares outstandingcash deployment

Risk Factors

  • Buyback may not be executed if cash needs arise for business development or operations
  • Forward-looking statements subject to risks including pricing negotiations and regulatory uncertainties

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302927094

Track record

29 reports on PTCT

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
  5. Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 3/10 Viewing Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
  7. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
  8. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
  9. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
  10. Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026